{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T21:01:03Z","timestamp":1783026063144,"version":"3.54.6"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2014,3,13]],"date-time":"2014-03-13T00:00:00Z","timestamp":1394668800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nervenarzt"],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1007\/s00115-013-3935-0","type":"journal-article","created":{"date-parts":[[2014,3,11]],"date-time":"2014-03-11T12:57:32Z","timestamp":1394542652000},"page":"417-426","source":"Crossref","is-referenced-by-count":17,"title":["Arzneimittelinteraktionen","Drug-drug interactions"],"prefix":"10.1007","volume":"85","author":[{"given":"E.","family":"Haen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,3,13]]},"reference":[{"key":"3935_CR1","doi-asserted-by":"crossref","unstructured":"Haen E (2002) Bedeutung von Arzneimittelsicherheitsnetzwerken f\u00fcr die Qualit\u00e4tssicherung der medikament\u00f6sen Depressionsbehandlung. In: Gastpar M, M\u00fcller WE (Hrsg) Depressionen. Versorgungsstrukturen und Behandlungsperspektiven. Springer, Berlin, S\u00a0119\u2013132","DOI":"10.1007\/978-3-642-55982-2_16"},{"key":"3935_CR2","unstructured":"z.\u00a0B. Interaktion Clozapin und Diazepam. In: Hiemke C, Dobmeier M, Eckermann G, Haen E (Hrsg) PSIAC \u2013 der Interaktionscomputer f\u00fcr die Psychiatrie. Springer, Heidelberg, 2006 (wird laufend aktualisiert). http:\/\/www.psiac.de"},{"key":"3935_CR3","unstructured":"K\u00f6stlbacher A, Hiemke C, Haen E et al (2007) PsiacOnline \u2013 Fachdatenbank f\u00fcr Arzneimittelwechselwirkungen in der psychiatrischen Pharmakotherapie. In: Osswald A, Stempfhuber M, Wolff C (Hrsg) Open Innovation. Proceedings des 10. Internationalen Symposions f\u00fcr Informationswissenschaften. Universit\u00e4tsverlag Konstanz, S\u00a0321\u2013326"},{"key":"3935_CR4","first-page":"S15","volume":"27","author":"Dobmeier","year":"2000","unstructured":"Dobmeier M, Haen E, Spindler P, Klein H (2000) Pharmakotherapie der Schizophrenie in den bayerischen Bezirkskrankenh\u00e4usern: Ergebnisse der AM\u00dcP Bayern. Psychiat Prax 27:S15\u2013S16","journal-title":"Psychiat Prax"},{"key":"3935_CR5","unstructured":"In: F\u00fclgraff-Palm: Lemmer B, Brune K (Hrsg) Pharmakotherapie\/Klinische Pharmakologie. 14.\u00a0Aufl. Springer Heidelberg, S\u00a029\u201352"},{"key":"3935_CR6","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1001\/archneur.56.5.595","volume":"56","author":"Aarsland","year":"1999","unstructured":"Aarsland D, Larsen JP, Cummins JL, Laake K (1999) Prevalence and clinical correlates of psychotic symptoms in parkinson disease: a community-based study. Arch Neurol 56:595\u2013601","journal-title":"Arch Neurol"},{"key":"3935_CR7","unstructured":"GlaxoSmithKline GmbH & Co KG: Fachinformation zu Requip\u00ae, Stand Juni 2013"},{"key":"3935_CR8","doi-asserted-by":"crossref","unstructured":"Bymaster FP, Hemrick-Luecke SK, Perry KW, Fuller RW (1996) Neurochemical evidence for antagonism by olanzapine of dopamine, serotonin, alpha 1-adrenergic and muscarinic receptors in vivo in rats. Psychopharmacology (Berl) 124:87\u201394","DOI":"10.1007\/BF02245608"},{"key":"3935_CR9","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0893-133X(97)00112-7","volume":"18","author":"Arnt","year":"1998","unstructured":"Arnt J, Skarsfeldt T (1998) Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology 18:63\u2013101","journal-title":"Neuropsychopharmacology"},{"key":"3935_CR10","first-page":"68","volume":"15","author":"Haen","year":"2004","unstructured":"Haen E, M\u00f6\u00dfner-Haug B (2004) Off-label-use bei Parkinson-Psychose. NeuroTransmitter 15:68","journal-title":"NeuroTransmitter"},{"key":"3935_CR11","first-page":"45","volume":"40","author":"Haen","year":"2013","unstructured":"Haen E, H\u00f6ffler D, Stammschulte T (2013) T\u00f6dliche Agranulozytose unter Novaminsulfon \u2013 aus Fehlern lernen. Arzneiverordnung in der Praxis 40:45\u201346","journal-title":"Arzneiverordnung in der Praxis"},{"key":"3935_CR12","first-page":"687","volume":"108","author":"Wenzel-Seifert","year":"2011","unstructured":"Wenzel-Seifert K, Wittmann M, Haen E (2011) QTc prolongation by psychotropic drugs and the risk of Torsade de Pointes. Dtsch Arztebl Int 108:687\u2013693","journal-title":"Dtsch Arztebl Int"},{"key":"3935_CR13","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1161\/01.CIR.30.1.17","volume":"30","author":"Selzer","year":"1964","unstructured":"Selzer A, Wray HW (1964) Quinidine Syncope. Paroxysmal ventricular fibrillation occurring during treatment of chronic atrial arrhythmias. Circulation 30:17\u201326","journal-title":"Circulation"},{"key":"3935_CR14","first-page":"25","volume":"19","author":"Wenzel-Seifert","year":"2012","unstructured":"Wenzel-Seifert K, Haen E (2012) Rote-Hand-Briefe zu Citalopram und Escitalopram. Psychopharmakotherapie 19:25\u201329","journal-title":"Psychopharmakotherapie"},{"key":"3935_CR15","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1055\/s-0031-1292489","volume":"44","author":"Haen","year":"2011","unstructured":"Haen E (2011) Therapeutic drug monitoring in pharmacovigilance and pharmacotherapy safety. Pharmacopsychiatry 44:254\u2013258","journal-title":"Pharmacopsychiatry"},{"key":"3935_CR16","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1055\/s-2006-940201","volume":"34","author":"Greiner","year":"2007","unstructured":"Greiner C, Haen E (2007) Therapeutisches Drug Monitoring in der Psychiatrie \u2013 Erstellung von Referenzbereichen f\u00fcr die Dosis-Konzentrations-Beziehung. Psychiat Prax 34:90\u201392","journal-title":"Psychiat Prax"},{"key":"3935_CR17","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1007\/s00115-008-2471-9","volume":"79","author":"Haen","year":"2008","unstructured":"Haen E, Greiner C, Bader W, Wittmann M (2008) Wirkstoffkonzentrationsbestimmungen zur Therapieleitung \u2013 Erg\u00e4nzung therapeutischer Referenzbereiche durch dosisbezogene Referenzbereiche. Nervenarzt 79:558\u2013566","journal-title":"Nervenarzt"},{"key":"3935_CR18","first-page":"138","volume":"12","author":"Haen","year":"2005","unstructured":"Haen E (2005) Bedeutung der klinisch-pharmakologischen Befundung von Wirkstoffkonzentrationsmessungen zur Therapieleitung. Psychopharmakotherapie 12:138\u2013143","journal-title":"Psychopharmakotherapie"},{"key":"3935_CR19","first-page":"129","volume":"19","author":"Haen","year":"2012","unstructured":"Haen E (2012) Der TDM-Befund. Psychopharmakotherapie 19:129\u2013134","journal-title":"Psychopharmakotherapie"},{"key":"3935_CR20","unstructured":"Wunderer H (2000) Arzneimittel richtig einnehmen: Wechselwirkungen zwischen Medikamenten und Nahrung; mit Einnahmeempfehlungen zu allen wichtigen Arzneistoffen. Govi, Eschborn"},{"key":"3935_CR21","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1046\/j.1365-2125.2000.00147.x","volume":"49","author":"Miceli","year":"2000","unstructured":"Miceli JJ, Wilner KD, Hansen RA et al (2000) Single- and multiple-dose pharmacokinetics of ziprasidone under nonfasting conditions in healthy male volunteers. Br J Clin Pharmacol 49:5","journal-title":"Br J Clin Pharmacol"},{"key":"3935_CR22","doi-asserted-by":"crossref","first-page":"3159","DOI":"10.1007\/s11095-011-0505-7","volume":"28","author":"Thombre","year":"2011","unstructured":"Thombre AG, Herbig SM, Alderman JA (2011) Improved ziprasidone formulations with enhanced bioavailability in the fasted state and a reduced food effect. Pharm Res 28:3159\u20133170","journal-title":"Pharm Res"},{"key":"3935_CR23","unstructured":"Ficht B (2001) Arzneistoffkonzentration im Organismus in Abh\u00e4ngigkeit von der Zeit: Pharmakokinetik im engeren Sinn. In: Forth W, Henschler D, Rummel W, F\u00f6rstermann U, Starke K (Hrsg) Allgemeine und spezielle Pharmakologie und Toxikologie, 8.\u00a0Aufl. Urban & Fischer, M\u00fcnchen, S\u00a056\u201377"},{"key":"3935_CR24","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1055\/s-0031-1286287","volume":"44","author":"Hiemke","year":"2011","unstructured":"Hiemke C, Baumann P, Bergemann N et al (2011) AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011. Pharmacopsychiatry 44:195\u2013235","journal-title":"Pharmacopsychiatry"},{"key":"3935_CR25","doi-asserted-by":"crossref","unstructured":"Grohmann R, R\u00fcther E, Schmidt LG (1994) Unerw\u00fcnschte Wirkungen von Psychopharmaka: Ergebnisse der AM\u00dcP-Studie. Springer, Berlin","DOI":"10.1007\/978-3-642-79126-0"},{"key":"3935_CR26","first-page":"93","volume":"17","author":"Haen","year":"1999","unstructured":"Haen E, Aigner J-M, Jost D et al (1999) Die Arzneimittel\u00fcberwachung in der Psychiatrie Bayerns (AM\u00dcP-Bayern). Arzneimitteltherapie 17:93\u201396","journal-title":"Arzneimitteltherapie"},{"key":"3935_CR27","first-page":"34","volume":"15","author":"Haen","year":"2004","unstructured":"Haen E (2004) AGATE: Qualit\u00e4tssicherung in der Psychopharmakotherapie. Neurotransmitter 15:34\u201343","journal-title":"Neurotransmitter"},{"key":"3935_CR28","first-page":"702","volume":"65","author":"Haen","year":"2010","unstructured":"Haen E (2010) Der Klinikverbund AGATE: Ein Pharmakokompetenzzentrum fl\u00e4chendeckend in und f\u00fcr Bayern. Bayer Arztebl 65:702\u2013703","journal-title":"Bayer Arztebl"},{"key":"3935_CR29","first-page":"238","volume":"18","author":"Haen","year":"2011","unstructured":"Haen E, Laux G (2011) Arzneimitteltherapiesicherheit\/Pharmakovigilanz in der klinischen Psychopharmakotherapie \u2013 Das Kliniknetzwerk AGATE. Psychopharmakotherapie 18:238\u2013243","journal-title":"Psychopharmakotherapie"},{"key":"3935_CR30","unstructured":"Haen E (2011) Die KinderAGATE. In: Rexroth CA Die klinische Kinder- und Jugendpsychiatrie in Bayern. Entwicklungen \u2013 Gegenwart \u2013 Perspektiven. V&R Unipress, G\u00f6ttingen, S\u00a0287\u2013306"},{"key":"3935_CR31","unstructured":"Satzung der Arbeitsgemeinschaft Arzneimitteltherapie bei psychiatrischen Erkrankungen (AGATE) e.\u00a0V., Stand 27.06.2012"},{"key":"3935_CR32","first-page":"64","volume":"152","author":"B\u00f6hm","year":"2012","unstructured":"B\u00f6hm R, Reinecke K, Haen E et al (2012) Arzneimittelinteraktionen \u2013 verstehen, vermitteln und vermeiden. Dtsch Apothek Z 152:64\u201374","journal-title":"Dtsch Apothek Z"}],"container-title":["Der Nervenarzt"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-013-3935-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00115-013-3935-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-013-3935-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,8]],"date-time":"2019-08-08T09:58:21Z","timestamp":1565258301000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00115-013-3935-0"}},"subtitle":["Interaktionen zwischen k\u00f6rperfremden Substanzen","Interactions between xenobiotics"],"short-title":[],"issued":{"date-parts":[[2014,3,13]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["3935"],"URL":"https:\/\/doi.org\/10.1007\/s00115-013-3935-0","relation":{},"ISSN":["0028-2804","1433-0407"],"issn-type":[{"value":"0028-2804","type":"print"},{"value":"1433-0407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,3,13]]}}}